Drugs / TDV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06665035 | Jun 2025 → Mar 2030 expected | dengue disease | Takeda | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06665035 ↗ |
| Modality | Vaccine | “Dengue Tetravalent Vaccine (TDV)” NCT06665035 ↗ |
| Route | Subcutaneous | “TDV 0.5 mL subcutaneous (SC) injection” NCT06665035 ↗ |